| Entry |
|
| Name |
Afelimomab (INN) |
| Class |
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG01936 TNF inhibitor
|
| Remark |
|
| Efficacy |
Immunosuppressant, Anti-TNF-alpha antibody |
| Type |
Monoclonal antibody |
| Target |
|
| Pathway |
| hsa04060 | Cytokine-cytokine receptor interaction |
| hsa04612 | Antigen processing and presentation |
| hsa04920 | Adipocytokine signaling pathway |
|
| Interaction |
|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AB Tumor necrosis factor alpha (TNF-alpha) inhibitors
L04AB03 Afelimomab
D07436 Afelimomab (INN)
Drug groups [BR:br08330]
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG01936 TNF inhibitor
D07436 Afelimomab
Target-based classification of drugs [BR:br08310]
Signaling molecules and receptors
Cytokines
Tumor necrosis factors
TNF (TNFA, TNFSF2)
D07436 Afelimomab (INN)
|
| Other DBs |
|
| LinkDB |
|